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4Shire, Development LLC Wayne, PA, USAA B S T R A C TObjective: To estimate the health resource use (HRU) and expenditure
of adult patients with attention deﬁcit/hyperactivity disorder (ADHD)
subsequently diagnosed with one or more mental health (MH)
comorbidities. Methods: Using Kaiser Permanente Southern Califor-
nia electronic medical records (January 1, 2006, to December 31, 2009),
we identiﬁed adults with at least one ADHD diagnosis and at least two
subsequent prescriptions ﬁlls for ADHD medication. The date of ﬁrst
MH comorbidity diagnosis after the index ADHD diagnosis was
deﬁned as the index transition date. Continuous eligibility 12 months
before and after the index transition date was required. For patients
with multiple transitions (Z2), the post-transition period reﬂected
the 12 months after the second transition. HRU for all-cause in-
patient, outpatient, emergency department, behavioral therapy, over-
all prescription ﬁll counts, and ADHD-speciﬁc prescription ﬁll counts
and mean patient expenditure (2010 US $) were estimated. General-
ized estimating equations were used to evaluate differences in HRU
and expenditure between the pre- and post-transition periods,ee front matter Copyright & 2014, International S
r Inc.
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ondence to: Aniket A. Kawatkar, Kaiser Permanentrespectively. Results: Of the 3809 patients with ADHD identiﬁed, 989
(26%) had at least one transition (n ¼ 357 single and n ¼ 632 multiple).
From the pre- to the post-transition period, for single transition
cohort, all HRU increased signiﬁcantly except for behavioral therapy.
In the multiple transition cohort, all HRU increased signiﬁcantly. Total
expenditure increased by mean  SE of $1822  $306 and $4432 
$301 (both P o 0.0001) in the single and multiple transition cohorts,
respectively. Conclusions: Twenty-six percent of patients with ADHD
transitioned to MH comorbid diagnoses. Increased HRU and expendi-
ture were associated with MH transitions. Identifying of patients with
ADHD at risk for MH comorbidities may help to improve their
outcomes.
Keywords: ADHD, comorbidity, expenditure, mental health, utilization.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Attention deﬁcit/hyperactivity disorder (ADHD) is generally con-
sidered a childhood condition, although it may clearly persist
into adulthood. Persistence rates into adulthood have been
reported to be as high as 50% to 60% of childhood-diagnosed
cases [1,2]. In addition, although approximately half of ADHD
cases are diagnosed before the age of 13 years, an estimated 35%
are not diagnosed until after age 18 years [3]. Even with this
knowledge, ADHD in adults has only recently become a focus of
the medical community [4,5]. The National Comorbidity Survey
Replication tracked the prevalence of attention deﬁcit/hyper-
activity symptoms and found that an estimated 4.4% of adults
aged 18 to 44 years experienced symptoms and some associateddisability [6], raising awareness about the longevity of ADHD and
the need for more research in the area of ADHD in adults.
Although there is increasing awareness of the signiﬁcant psy-
chosocial outcomes associated with ADHD in adults, only a few
studies have evaluated ADHD expenditure in adults and its
economic burden on the health care system [2–7]. ADHD contrib-
utes to rising costs for payers, employers, and patients in both
direct and indirect costs [8]. Of the limited research available,
studies demonstrate signiﬁcantly higher annual medical costs
among adults with ADHD (ranging from $4929 to $5651, in 2005
US $) than among matched controls (ranging from $1473 to $2771,
in 2005 US $) when controlling for comorbidities [8,9]. Hodgkins
et al. [10] have reported that annual productivity losses of $4403
(2006 US $) (including absences, short-term disability leave, andociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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health care costs of $4306 (including inpatient, emergency
department visit, outpatient visit, other outpatient services, and
outpatient prescriptions expenditure) in adult patients with
ADHD [10].
Independent of ADHD, psychiatric comorbidities may have an
even more profound effect on costs, with annual estimates
totaling $58.3 billion for drug abuse, $85.8 billion for alcohol
abuse, and $43.7 billion for depression [11,12]. A study estimating
treatment costs for children with ADHD plus comorbidities
versus ADHD alone found that comorbid psychiatric disorders
substantially increased the costs of treatment [13]. Indirect costs
of ADHD also contribute signiﬁcantly to the burden of disease,
particularly for patients and employers [9,14]. The symptoms of
ADHD can lead to decreased academic and workplace perform-
ance, increased absenteeism, short-term disability, worker’s
compensation claims, and subsequent loss of income or even
employment [15,16].
Currently, little is known about the health care resource
utilization and cost impact of adult patients with ADHD sub-
sequently diagnosed with one or more comorbid mental health
(MH) conditions. Because ADHD in adults often coexists with
other comorbidities [6], including conduct disorder, obsessive
compulsive disorder, and depression, diagnosis and treatment
are often compromised. These MH comorbid conditions may
potentially amplify the use of health care resources and raise
the risk of adverse long-term outcomes for patients, including
violence and substance abuse [7,8]. Before exploring cost-
effective approaches that can reduce the effect of future MH
comorbidities in adult patients with ADHD, we ﬁrst need to
understand whether the associations of mental disorders with
subsequent expenditure are strong enough and their magnitude
justiﬁes the introduction of such interventions. The objective of
this study was to estimate the incremental expenditure in adult
patients with ADHD who were subsequently diagnosed with
predeﬁned comorbid MH conditions.Methods
Study Population
The study population included members from the Kaiser Perma-
nente Southern California (KPSC) managed care population who
were diagnosed and treated for ADHD. The KPSC is an integrated
health care system that provides comprehensive health services
to approximately 3.5 million residents of Southern California. The
population served by the KPSC is socioeconomically diverse and
broadly representative of the racial/ethnic groups living in South-
ern California [17]. Members enroll through the Kaiser Foundation
Health Plan for prepaid health care insurance, including pharma-
ceutical beneﬁts. The KPSC region includes 14 hospitals and more
than 198 medical ofﬁces by a partnership of more than 5700
physicians who comprise the entire range of medical specialists.
Data Source
The primary data source was KPSC electronic medical records,
which contain detailed accounts of interactions of members with
the health care system. Data on resource utilization were extracted
from research data sets created from the electronic medical records
that included comprehensive information on inpatient and out-
patient utilization, emergency department visits, diagnoses, proce-
dures, vital signs, laboratory, and pharmacy. Information from
external medical claims was also extracted to include services
and care provided outside of the KPSC. Patients’ demographic and
health plan enrollment information was obtained from KPSCmembership databases and augmented by mapping geocoded
income and education-level information by census tract.
Study Design
This was a retrospective cohort study among members of the
KPSC health plan identiﬁed as those diagnosed and treated for
ADHD between January 1, 2006, and December 31, 2009. Health
care and prescription utilization data were obtained from KPSC
electronic medical records and external claims, whereas direct
medical expenditure data were obtained by weighting the uti-
lization counts with nationally representative reimbursement
scales [18]. The study was approved by the KPSC Institutional
Review Board.
Patient Inclusion
Using KPSC electronic medical records from January 1, 2005, to
December 31, 2009, we identiﬁed adult patients (aged 18–100
years) with at least one ADHD diagnosis (using International Classi-
ﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation [ICD-9-CM]
codes 314.0, 314.00, 314.01, and 314.9) and at least two dispensing
records for Food and Drug Administration–approved ADHD med-
ications prescribed after the diagnosis. The requirement of active
pharmacological treatment for ADHD was imposed to identify the
subset of adult patients with ADHD who were not only diagnosed
with ADHD but also treated with a pharmacologic agent as
conﬁrmatory. The ﬁrst medical record satisfying the diagnosis
and prescription criteria for ADHD was identiﬁed as the index
ADHD diagnosis (Fig. 1). Continuous health plan eligibility was
required for the entire 4-year duration of the study.
Exclusions
To avoid the inclusion of patients using stimulants for non-ADHD
conditions, individuals with evidence of the following conditions
within the 12-month preindex period were excluded from the
analysis: narcolepsy (ICD-9-CM code 347.X), poststroke (ICD-9-CM
codes 430.xx, 431.xx, 432.xx, 433.01, 433.11, 433.21, 433.31, 433.81,
433.91, 434.xx, and 436.xx), and early dementia (ICD-9-CM codes
290.xx, 294.1x, 294.8x, 331.0, 331.1x-9x, and 797.xx). If a patient
with ADHD had any MH comorbidity diagnosis in the 12-month
period before the ADHD index diagnosis, they were excluded so
that the cohort represented patients with ADHD with subsequent
(predeﬁned) MH comorbidity, as opposed to patients with MH
conditions who may develop ADHD as comorbidity. Last, patients
who did not have any transition during the follow-up period were
also excluded.
MH Transition
MH transition was deﬁned as the occurrence of one or more
predeﬁned MH condition diagnosed after the index ADHD diag-
nosis. The date of the ﬁrst MH comorbidity diagnosis code
(oppositional deﬁant disorder, generalized anxiety disorder, con-
duct disorder, major depressive disorder, bipolar disorder, anti-
social personality disorder, social phobia disorder, or substance
abuse disorder) was deﬁned as the index transition date (ITD)
(Fig. 1). Depending on the number of additional predeﬁned MH
conditions experienced during follow-up, two mutually exclusive
cohorts were created. Patients with ADHD diagnosed with only
one predeﬁned MH condition were categorized in the single
transition cohort, whereas those experiencing two or more differ-
ent MH conditions were categorized in the multiple transition
cohort. The pretransition period was deﬁned as the 12 months
before ITD, whereas the posttransition period included the 12
months after the ITD if a patient had a single MH comorbidity.
For patients with two or more different transitions, the
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Fig. 1 – Illustration of mental health transitions in patients with ADHD. ADHD, attention deﬁcit/hyperactivity disorder;
ADHD þ1, patients with ADHD with single mental health transition after the index date; ADHD þ2, patients with ADHD with
multiple mental health transitions after the index date; Tx date, transition index date.
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of the second comorbidity diagnosis. The single MH comorbidity
cohort and the cohort experiencing two or more MH conditions
were mutually exclusive. The time period until the MH transition
occurred could vary. In addition, patients were required to have at
least 1-year post-transition follow-up data before the end of the
study so that utilization and expenditures for the entire 1-year
post-transition period were accounted. Hence, the last transition
date for any patient was December 31, 2008, or earlier.
Outcomes
Utilization
All-cause health care resource utilization and expenditure
were estimated in the pre- and post-transition periods to
evaluate change after a transition to MH comorbidity. All-
cause health care resource utilization included counts of out-
patient visits, behavior therapy visits, emergency department
visits, inpatient visits, length of inpatient stay (in days), and
pharmacy ﬁlls (ADHD-speciﬁc and all-cause prescription ﬁlls).
The duration of both pre- and post-transition periods was 12
months.
Expenditure
For enhanced generalizability, costs were assigned to health
care services by using the Medicare Resource Based Relative
Value Scale multipliers for medical utilization [18], average
wholesale price for prescription utilization, and per diem
amounts for inpatient stays. Resource-based relative value
multipliers are based on Current Procedural Terminology codes
and are published under the Physician Fee Schedule in the
Federal Register [19]. Drug costs were estimated by matching
average wholesale drug prices to pharmacy National Drug
Codes. Inpatient hospitalizations included one or more days
stay from KPSC’s hospitalization data and further classiﬁed as
stays with surgery and without surgery. The median per day
hospitalization expenditure was calculated from the expendi-
ture data (paid cost) reported in the 2007 Medical Expenditure
Panel Survey inpatient encounter data for those who had
surgery during an inpatient stay ($3402.25 per day) and for
those who did not have surgery ($1814.86 per day) during an
inpatient stay. An aggregate total expenditure variable was
created as summation of all-cause expenditure associated withoutpatient visits, emergency department visits, inpatient vis-
its, and pharmacy utilization. All expenditures were inﬂated to
the 2010 US $ using the medical component of the consumer
price index [20].
Statistical Analysis
Descriptive statistics including mean, and standard errors for con-
tinuous variables and frequencies and percentages for categorical
variables, were calculated. Negative binomial models were used to
evaluate differences in utilization counts, whereas generalized linear
models with log-link function and gamma distribution were used to
compare expenditure differences during the pre- and post-transition
periods. The study design compared the incremental difference
between the pre- and post-transition period for the same patient.
This paired matching mitigated time invariant sources of selection
bias. Essentially, each subject served as his or her own control,
allowing us to identify unbiased incremental differences in expen-
ditures and utilization. To address the effects of possible correlation
caused by nonindependent samples, generalized estimating equa-
tions were used to solve outcome models. The generalized estimat-
ing equation uses a working correlation matrix to correct the bias in
standard errors caused by correlated observations on same subjects.
All data management and analyses were conducted using the
Statistical Analysis System (SAS, version 9.1).Results
During the study period from 2006 to 2009, a total of 6014 incident
adult patients with ADHD were identiﬁed. Of these, 3809 adult
patients with ADHD met the eligibility criteria and 989 (26%) had
at least one transition to a subsequent MH condition after ADHD
diagnosis within our study time frame. Among the 989 patients,
357 had a single transition and 632 had multiple transitions
during follow-up. Table 1 provides descriptive statistics of
patients’ demographic characteristics for the transition cohorts.
The mean age was similar for those with a single transition (34.5
 14.4 years) and for those with multiple transitions (34.7  14.4
years). The single transition cohort was comprised predomi-
nantly of men (60.8%); however, there were slightly more women
(50.6%) in the multiple transition cohort. Differences in racial
composition were evident where the group with multiple MH
transitions had a slightly higher number of Caucasians (57.3%)
Table 1 – Patient characteristics by transition cohort.
Characteristic Total with transitions Single transition Multiple transitions
Total 989 (100.0) 357 (100.0) 632 (100.0)
Age (y)
18–21 298 (30.1) 114 (31.9) 184 (29.1)
22–24 82 (8.3) 36 (10.1) 46 (7.3)
25–34 143 (14.5) 41 (11.5) 102 (16.1)
35–44 161 (16.3) 58 (16.3) 103 (16.3)
45–54 203 (20.5) 76 (21.3) 127 (20.1)
55–64 89 (9.0) 27 (7.6) 62 (9.8)
65þ 13 (1.3) 5 (1.4) 8 (1.3)
Sex
Female 460 (46.5) 140 (39.2) 320 (50.6)
Male 529 (53.5) 217 (60.8) 312 (49.4)
Race
White 535 (54.1) 173 (48.5) 362 (57.3)
Hispanic 311 (31.5) 127 (35.6) 184 (29.1)
Black 31 (3.1) 15 (4.2) 16 (2.5)
Asian/Paciﬁc Islander 24 (2.4) 9 (2.5) 15 (2.4)
Others 45 (4.5) 16 (4.5) 29 (4.6)
Unknown 43 (4.4) 17 (4.8) 26 (4.1)
Insurance type
Employer paid 837 (84.6) 307 (86.0) 530 (83.9)
Government paid* 45 (4.6) 16 (4.5) 29 (4.6)
Other 107 (10.8) 34 (9.5) 73 (11.6)
Income†
0–24,999 15 (1.5) 9 (2.5) 6 (1.0)
25,000–49,999 166 (16.8) 59 (16.5) 107 (16.9)
50,000–74,999 312 (31.6) 105 (29.4) 207 (32.8)
75,000–99,999 238 (24.1) 79 (22.1) 159 (25.2)
100,000 and up 258 (26.1) 105 (29.4) 153 (24.2)
Charlson comorbidity index
0 839 (84.8) 302 (84.6) 537 (85.0)
1 114 (11.5) 45 (12.6) 69 (10.9)
Z2 36 (3.6) 10 (2.8) 26 (4.1)
Mental health conditions
Oppositional deﬁant disorder 6 (0.6) 3 (0.8) 3 (5.1)
Conduct disorder 4 (0.4) 2 (0.6) 2 (0.3)
Antisocial personality disorder 2 (0.2) 0 (0) 2 (0.3)
Social phobia 42 (4.6) 4 (1.1) 38 (6)
Bipolar disorder 60 (6.1) 10 (2.8) 50 (7.9)
Major depressive disorder 475 (48.0) 114 (31.9) 361 (57.1)
General anxiety disorder 513 (51.9) 126 (35.3) 387 (61.2)
Substance abuse disorder 336 (34.0) 98 (27.5) 238 (37.7)
Note. Values are n (%).
* Government-paid insurance includes Medicare, Medicaid, or both Medicare/Medicaid.
† Income refers to annual household income (US $) in the census tract where the subject resided.
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single transition group (Caucasians, 48.5%; Hispanics, 35.6%).
There were no marked differences between insurance type,
income, or the number of Charlson comorbidities [21,22] between
the single and multiple transition cohorts.
Pre-Post Transition Changes for Patients with a Single
Transition
Among patients with a single transition, the mean number of
annual visits increased signiﬁcantly from the pre- to the post-
transition period for most of the utilization types with the
exception of behavioral therapy and inpatient length of stay
(Table 2). Although behavioral therapy visits (mean  standard
error) decreased from 2.15  0.38 to 0.79  0.17 (P ¼ 0.0006), thelength of stay for inpatient visits did not change signiﬁcantly
(1.05 0.45 to 2.07  0.37 ; P ¼ 0.18).
Similar trends were observed for all-cause health care expen-
ditures, again with the exception of behavioral therapy visits.
Average outpatient expenditure did not change signiﬁcantly from
the pre-transition period ($1006  $53) to the post-transition
period ($1147  $69) (P ¼ 0.08). Emergency department expendi-
ture ($142  $17 to $254  $22), inpatient expenditure ($1900 
$814 to $3757  $668), all-cause prescription expenditure ($2928 
$255 to $4345  $381), and ADHD-speciﬁc prescription expendi-
ture ($881  $58 to $1057  $64) increased signiﬁcantly (all P o
0.05) (Table 3). Behavioral therapy expenditure decreased signiﬁ-
cantly from $163  $29 to $57  $13 (P o 0.0001). Overall total
expenditure ($4177  $298 to $5981  $436) increased by $1822 
$306 and was statistically signiﬁcant (P o 0.0001) (Table 3).
Table 2 – All-cause health care utilization pre- and post-transition (single transition).
Resource utilization N Mean  SE P* for post-pre
difference
Pretransition Post-Transition Post-pre difference
Outpatient visits 357 8.21  0.42 9.28  0.54 1.07  0.54 0.0451
Emergency department visits 121 0.57  0.07 1.01  0.08 0.45  0.13 0.0003
Behavioral therapy visits 52 2.15  0.38 0.79  0.17 1.48  0.43 0.0006
Inpatient visits 43 0.44  0.11 0.91  0.13 0.48  0.23 0.032
Length of stay 43 1.05  0.45 2.07  0.37 1.06  0.79 0.1793
ADHD medications 321 2.38  0.12 2.85  0.14 0.47  0.16 0.0042
All medications 353 10.79  0.62 12.28  0.61 1.49  0.40 0.0002
ADHD, attention deﬁcit/hyperactivity disorder; SE, standard error.
* P value for difference between pre- and post-transition utilization counts assuming negative binomial family distribution and log link in a
generalized linear model.
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Transitions
Among patients with multiple transitions (where the post-
transition period was deﬁned as the period after the diagnosis of
a different second MH condition), the mean number of visits also
increased signiﬁcantly from the pre- to the post-transition period
within all utilization categories including behavioral therapy (all
P o 0.05) (Table 4). The magnitude of increase was quite large in
case of outpatient visits (64% increase), all-cause prescription
utilization (46% increase), and length of hospital stay (nearly ﬁve
times higher) from the pre- to the post-transition period.
This higher utilization resulted in a signiﬁcantly higher expen-
diture in all categories of utilization including behavioral therapy.
Average outpatient expenditure increased signiﬁcantly from $1059
 $44 in the pretransition period to $1778 $73 post-transition (Po
0.001). Similarly, emergency department expenditure ($191  $15 to
$306  $23), inpatient expenditure ($1367  $336 to $8058  $1511),
all-cause prescription expenditure ($2750  $174 to $5348  $257),
and ADHD-speciﬁc prescription expenditure ($762  $48 to $1224 
$59) increased signiﬁcantly (all Po 0.05) (Table 5). Total expenditure
($4061  $196 to $8313  $397) increased by $4432  $301 and was
statistically signiﬁcant (P o 0.0001).Discussion
The objective of this study was to estimate the incremental direct
medical expenditure in adult patients with ADHD who were
subsequently diagnosed with comorbid MH conditions. Of theTable 3 – All-cause health care expenditure ($) pretransi
Expenditure N Mean
Pretransition Posttrans
Outpatient 357 1006  53 1147  6
Emergency department 121 142  17 254  2
Behavioral therapy 52 163  29 57  1
Inpatient 43 1900  814 3757  6
ADHD medications 321 881  58 1057  6
All medications 353 2928  255 4345  3
Overall expenditure† 357 4177  298 5981  4
ADHD, attention deﬁcit/hyperactivity disorder; SE, standard error.
* P value for difference between pre- and post-transition expenditure assu
† Overall expenditure is the sum of total cost from outpatient, inpatient3809 adult patients with ADHD identiﬁed in this study, 989 (26%)
were subsequently diagnosed with at least one MH comorbidity,
with the large majority (64%) among these 989 patients having
two or more MH transitions. In this cohort with multiple tran-
sitions, behavioral therapy expenditure increased by 40%, ADHD
medications expenditure increased by 61%, while total expendi-
ture as well as all-cause medications expenditure nearly doubled
in the post-transition period. In addition, in the same cohort,
post-transition outpatient expenditure increased by 68%, emer-
gency department expenditure increased by 60%, while inpatient
expenditure was nearly ﬁve times higher as compared with that
in the pretransition period. These ﬁndings indicate that subse-
quent diagnosis of MH comorbidities in adult patients with ADHD
resulted in a signiﬁcant increase in overall health care utilization
and expenditure that will substantially increase the overall
burden of ADHD. They also provide a strong economic justiﬁca-
tion to explore cost-effective interventions that can reduce the
effect of future MH comorbidities in adult patients with ADHD.
Furthermore, physicians treating adults diagnosed with ADHD
should carefully screen for other MH comorbidities.
These ﬁndings are consistent with published studies that have
reported higher utilization and expenditure associated with
patients with ADHD with MH comorbidities [8,23–28]. Previous
studies comparing patients with ADHD with control populations
in both pediatrics [29,30] and adults[8,9,31] suggest that patients
with ADHD yield higher expenditure than do non-ADHD controls,
even after controlling for patient comorbidities [8]. To our knowl-
edge, this is the ﬁrst study in adult patients with ADHD to conﬁrm
the magnitude and effect of additional MH disorders on utilization
and expenditures. Subsequent comorbid MH diagnoses may betion and post-transition (single transition).
 SE P* for post-pre difference
ition Post-pre difference
9 141  68 0.08
2 115  34 o0.0001
3 117  32 o0.0001
68 1929  1436 0.002
4 176  67 0.02
81 1435  223 o0.0001
36 1822  306 o0.0001
ming gamma distribution and log link in a generalized linear model.
, and emergency department visits and all-cause medications.
Table 4 – All-cause health care utilization pretransition and post-transition (multiple transitions).
Resource utilization N Mean  SE P* for post-pre
difference
Pretransition Posttransition Post-pre difference
Outpatient visits 632 8.83  0.36 14.50  0.58 5.79  0.57 o0.0001
Emergency visits 268 0.73  0.05 1.19  0.08 0.47  0.10 o0.0001
Behavioral therapy visits 182 1.46  0.12 2.03  0.27 0.57  0.28 0.0403
Inpatient visits 85 0.35  0.06 1.21  0.16 0.96  0.20 o0.0001
Length of stay 85 0.75  0.19 4.39  0.84 4.53  0.87 o0.0001
ADHD medications 564 1.98  0.09 3.12  0.10 1.16  0.12 o0.0001
All medications 629 12.03  0.44 17.65  0.61 5.68  0.42 o0.0001
ADHD, attention deﬁcit/hyperactivity disorder; SE, standard error.
* P value for difference between pre- and post-transition utilization counts assuming negative binomial family distribution and log link in a
generalized linear model.
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substance abuse and other at-risk health behaviors, which may
lead to further medical expenditures.
As compared with other utilization categories, behavioral
therapy utilization counts declined signiﬁcantly in the single
transition cohort but increased signiﬁcantly in the multiple
transition cohort. In the single transition cohort, this ﬁnding
may be indicative of satisfaction with pharmacotherapy treat-
ment options and consequently, there may be less focus on
behavior therapy. If medications are working well and keeping
symptoms under control, the patient and/or physician may not
feel that behavioral therapy is necessary. Because this is a
population also afﬂicted with one or more comorbid disorders,
however, one may expect that behavioral therapy would be an
important component of treatment. Behavioral therapy may be
underutilized in this population because presently, no nationally
recognized treatment guidelines exist for ADHD in adults.
Another plausible explanation may be that patients are seeking
behavioral therapy outside of the KPSC health plan and therefore
this information may not be accurately accounted within our
data. This explanation is consistent with a study that found that
a signiﬁcant number of commercially insured individuals
received outpatient MH care out of network, particularly those
receiving psychotherapy [32]. In the multiple transition cohort
though, utilization counts of behavior therapy increased by 40%
on average. Further research on the use of behavior therapy
within adult populations with ADHD is important in understand-
ing how it relates to treatment outcomes.
Utilization and expenditure were signiﬁcantly higher, on
average, for patients with two or more MH transitions than for
those with a single transition, suggesting incremental economicTable 5 – All-cause health care expenditure ($) pretransi
Expenditure N
Pretransition Pos
Outpatient 632 1059  44 17
Emergency department 268 191  15 3
Behavioral therapy 182 109  10 1
Inpatient 85 1367  336 80
ADHD medications 564 762  48 12
All medications 629 2750  174 53
Overall expenditure† 632 4061  196 83
ADHD, attention deﬁcit/hyperactivity disorder; SE, standard error.
* P value for difference between pre- and post-transition expenditure assu
† Overall expenditure is the sum of total expenditure from outpatient, inpburden with the addition of psychiatric comorbid conditions. As
compared with the pretransition period, most utilization in the
post-transition period for the multiple transition cohort
increased by more than 60%; however, in the single transition
cohort, only emergency visits and inpatient expenditure
increased by more than 50%. Nevertheless, the trend in increases
in resource use and expenditure in pre- to post-MH transition
change was similar in direction (though not in magnitude) across
both the single and multiple transition cohorts, except for
behavioral therapy, inpatient length of stay, and outpatient
expenditures. Our ﬁndings support the previous literature in
other chronic conditions, which suggests that patients with
comorbid psychiatric conditions were more likely to have emer-
gency care and high primary care utilization [33]. This study
expands on the previous literature by quantifying the incremen-
tal expenditure of MH comorbidities in adult patients with ADHD.
From a health policy perspective, these ﬁndings underscore
the need for resource allocation toward cost-effective and efﬁ-
cient preventive interventions, management, and pharmacolog-
ical treatment for the cohort of patients with ADHD who are more
likely to experience additional MH comorbidities. This may not
only potentially save downstream costs but also positively affect
the quality of life and productivity of these patients [34]. The
incremental expenditures identiﬁed in our study provide the
lower bounds of expected future cost-savings associated with
such interventions if they allow affected individuals to lead a
normal life. Future research should identify which preventive
interventions not limited to behavioral and medical therapies can
provide cost-effective outcomes for this population. Private and
public payers may want to consider such research or the creation
of algorithms to help identify patients who may be at risk totion and post-transition (multiple transition).
Mean  SE P* for post-pre
difference
t-transition Post-pre difference
78  73 734  70 o0.0001
06  23 118  27 o0.0001
53  20 44  21 0.001
58  1511 8359  1583 o0.0001
24  59 470  60 o0.0001
48  257 2693  185 o0.0001
13  397 4432  301 o0.0001
ming gamma distribution and log link in a generalized linear model.
atient, and emergency department visits and all-cause medications.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 6 1 – 6 6 8 667develop a comorbid MH to potentially intervene earlier and
prevent downstream costs. Because the cost-effectiveness of
interventions may differ between patients with single transitions
and patients with multiple transitions, an initial ﬁrst step may be
to identify and/or develop screening tools or predictive models to
identify those patients with ADHD who are most likely to
transition to additional MH comorbidities.
Study limitations
Indirect costs were not assessed as part of this study. We hypothe-
size that the burden due to work loss, or other indirect costs of
comorbid disorders, would add incremental expenditure to the
overall cost of illness, and future research could evaluate these
effects. Our ﬁndings may have limited generalizability beyond the
KPSC population if adult patients with ADHD are treated differently
in fee-for-service health plans, or if signiﬁcant variations exist
because of patient or plan characteristics. In addition, by excluding
patients with ADHD who did not use pharmacological treatment,
our ﬁndings of incremental resource use are more generalizable to
the diagnosed and treated population and may not be representa-
tive of the entire ADHD diagnosed population if such patients
experience differential utilization patterns. Conversely, we are also
ensuring that these patients were more likely to tolerate their
ADHD medication and/or respond to their medications, because if
they were not, they may have discontinued the treatment.
In terms of study design, we had required a limited 12-month
period before the index ADHD diagnosis where MH comorbidities
diagnosis codes were not observed. MH conditions, however, may
have been present before this 12-month preindex period. Also, a
matched control group that did not transition to MH comorbidity
for comparison between groups could have further reinforced our
inferences. In regard to the follow-up period, because the time to
second (or higher) transition was not restricted, the multiple
transition cohort may have experienced the second transition
signiﬁcantly later than the ﬁrst transition. Thus, by not control-
ling for time effects, we may have introduced bias, if health
technologies, treatment, or diagnostic guidelines changed signiﬁ-
cantly between the pre-post transition periods.
Our approach of applying standardized costing weights poses
additional limitations. Standardized resource assignment is
unlikely to reﬂect a speciﬁc provider’s cost of producing health
services because it does not capture the resources used in a
speciﬁc setting (e.g., speciﬁc to the KPSC) but reﬂects a broader
assessment of the relative resources required to deliver health
care services. Thus, relative value–based approaches capture
expected, standardized resource use rather than the actual costs
experienced within KPSC’s speciﬁc setting. The use of per-diem
reimbursement for inpatient stay and discounted average whole-
sale price for pharmaceuticals has similar consequences although
these are common approaches used in health services research.
Last, this study is subject to the traditional limitations of
retrospective research including the lack of physician charts to
conﬁrm diagnoses of ADHD, as well as the use of ICD-9 codes,
which could be prone to errors in the coding of diagnosis [35].Conclusions
In adult patients with ADHD, the increase in MH comorbidities
was associated with an increase in health care utilization and
expenditure as compared with the period with no MH comorbid-
ities. From a value assessment perspective, adult patients with
ADHD may need to be monitored routinely for the presence of
other MH comorbidities with the goal of reducing future expen-
ditures through early interventions. Clinicians and health caredecision makers should be aware of the effect that comorbid MH
conditions have on utilization and expenditure in adult patients
with ADHD. We also need to better understand the relationship
between current management approaches and health outcomes
and look for more effective and efﬁcient ways to treat adult
patients with ADHD to reduce the chances of future MH tran-
sitions. Further research is necessary to improve the under-
standing of the long-term relationship between adults with
ADHD and comorbid conditions.Acknowledgments
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